Literature DB >> 15279697

Pathogenesis of respiratory syncytial virus infection.

Ralph A Tripp1.   

Abstract

Respiratory syncytial virus (RSV) is recognized as the most important cause of serious lower respiratory tract illness in infants and young children worldwide causing repeat infections throughout life with serious complications occurring in the elderly and immune compromised patient. The level of disease pathogenesis associated with RSV infection is balanced between virus elimination and the nature of the immune response to infection. The innate and adaptive immune responses to RSV infection are not fully elucidated; however, significant progress has been made in understanding the virus-host relationship and mechanisms associated with disease pathogenesis. This review summarizes important aspects of these findings, and provides current perspective on processes that may contribute to RSV disease pathogenesis. Copyright Mary Ann Liebert, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15279697     DOI: 10.1089/0882824041310513

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  47 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

3.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

5.  Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease.

Authors:  Lucas Zimon Giacomini Ribeiro; Ralph A Tripp; Lívia Maria Gonçalves Rossi; Patrícia Vianna Bonini Palma; Jonny Yokosawa; Orlando Cesar Mantese; Thelma Fátima Mattos Oliveira; Lysa Luiz Nepomuceno; Divina Aparecida Oliveira Queiróz
Journal:  J Clin Immunol       Date:  2007-10-20       Impact factor: 8.317

6.  Respiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.

Authors:  Elizabeth A Turpin; Aurita Antao-Menezes; Mark F Cesta; James B Mangum; Duncan G Wallace; Edilberto Bermudez; James C Bonner
Journal:  Respir Res       Date:  2010-02-22

7.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

8.  Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Authors:  Olivia Perwitasari; Scott Johnson; Xiuzhen Yan; Elizabeth Howerth; Sharon Shacham; Yosef Landesman; Erkan Baloglu; Dilara McCauley; Sharon Tamir; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

9.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

10.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.